Morphogenetic pathways govern the processes that underlie embryonic development as well as self-renewal and homeostasis in adult tissues. The Genetics Company (TGC) exploits the untapped potential of morphogenetic pathways to develop new therapeutic approaches to human diseases with an initial focus on cancer and type-2 diabetes. TGC has established Morphogenetics(TM) as a proprietary strategy: To identify and validate novel modulators of tissue and organ development for new therapeutic applications, ranging from the morphogenetic remodeling of tumors to in vitro tissue engineering and organ regeneration To identify new drug targets through in vivo saturation mutagenesis in Drosophila To identify small compounds by means of an innovative in vivo screening technology in Drosophila (InvoScreen(TM)).